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Ventilator-associated pneumonia (VAP) remains a 
diagnostic dilemma.[1] New-onset fever, leucocytosis, 
changes in chest auscultation, radiology and lung 
function and a positive bacterial culture suggest VAP, 
but do not necessarily confirm it. Overdiagnosis of 
VAP on clinical and radiological grounds may occur in up to 50% 
of patients, leading to inappropriate overuse of broad-spectrum 
antimicrobials, which is a major determinant of bacterial resistance, 
whereas failure to treat established VAP is reported to increase 
morbidity and mortality.[1] Guidelines continue to evolve as the 
definitions for VAP change in an effort to clarify a complex clinical 
condition and identify those patients who require therapy.[2] Recent 
Centers for Disease Control (CDC) guidelines[3] propose a tiered 
approach to VAP and the division of infection-related ventilator-
associated complications into possible and probable VAP. A change 
in temperature and white blood cell count, worsening oxygenation, 
purulent secretions and the empirical prescription of antimicrobials 
are prerequisites for both categories. In addition, a diagnosis of 
possible VAP requires either purulent secretions or a positive 
bacterial culture of sputum, whereas a diagnosis of probable VAP 
requires purulent secretions and specific quantitative analysis of 
either an endotracheal aspirate (ETA) or more invasive specimens 
from bronchoalveolar lavage, a protected specimen brush, pleural 
fluid or lung tissue. In the absence of purulent secretions, diagnostic 
tests for Legionella or a number of viruses are recommended. In 
both possible and probable VAP, specimens containing normal 
respiratory or oral flora, Candida, coagulase-negative staphylococci 
or enterococci are excluded. Given the absolute criterion that 
antimicrobials need to be administered in both categories, these 
divisions do not reduce unnecessary prescriptions and will have little 
impact on curbing bacterial resistance.
Whether possible or probable, VAP is defined as pneumonia 
occurring after 48 hours of endotracheal intubation and mechanical 
ventilation. The American Thoracic Society guidelines[4] divide 
VAP into early (starting on days 3 and 4) and late (starting on 
day 5 or thereafter). Regardless of the time of onset of suspected 
VAP, initial antimicrobial therapy will of necessity be empirical 
until microbiology results become available. The recommendation 
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is to use broad-spectrum drugs and de- 
escalate when sensitivities are reported. [5] 
Delays in microbiology results or marked 
improvement in the patient’s clinical 
condition may perpetuate use of the initial 
choice of antimicrobial, a potent stimulus for 
multidrug bacterial resistance. Recent work 
suggests that where there is diagnostic doubt, 
delaying antimicrobials until culture results 
are available does not increase mortality and 
in fact may improve survival.[6]
The antimicrobial policy in the Trauma 
Intensive Care Unit (TICU) at Inkosi 
Albert Luthuli Central Hospital (IALCH), 
Durban, South Africa, is to treat probable 
VAP empirically but to await microbiological 
results before treating possible VAP. We 
embarked on a prospective observational 
study in the TICU with a view to deter-
mining whether delaying antimicrobial 
prescriptions in patients with possible VAP 
until microbiology results became available 
made any difference to outcome.
Methods
The study was approved by the Bioethics 
Committee of the University of KwaZulu-
Natal, Durban (BE 207/09), as part of the 
class approval covering the unit data. All 
patients admitted to the TICU at IALCH 
who required mechanical ventilation for 
>48 hours were considered for inclusion 
in the study, which was conducted pro-
spectively for the 12-month period January - 
December 2014. Patients in whom aspiration 
was suspected before or during endotracheal 
intubation, those in whom a positive 
culture was obtained within the first 48 
hours, and those who did not conform 
to the CDC criteria were excluded. The 
diagnostic criteria for probable VAP were the 
combination of new-onset fever of ≥38.4oC, 
purulent secretions in an ETA, changes in 
chest auscultation or radiographs, a rise in 
the white cell count, a deterioration in lung 
function manifested by a reduction in the 
partial pressure of arterial oxygen/fraction 
of inspired oxygen ratio, reduced compliance 
and an elevated procalcitonin level. Possible 
VAP was defined similarly, but without 
marked changes in chest auscultation, 
radiology or pulmonary function. Early 
VAP was defined as occurring on the 
3rd or 4th days of mechanical ventilation 
and late VAP as starting on or beyond 
day 5. All microbiology specimens were 
submitted as ETAs, and more invasive 
diagnostic tests were not undertaken. 
Specimens were processed by the National 
Health Laboratory Service (NHLS), where 
processing, identification of pathogens 
and susceptibility testing were conducted 
according to standard NHLS operating 
procedures.[7] Patients who fulfilled the 
criteria for probable VAP were commenced 
on empirical antimicrobial therapy as per 
the antimicrobial protocol in the TICU at 
IALCH, which is based on microbiological 
surveillance. The antimicrobial of choice for 
early-onset VAP is amoxicillin/clavulanic 
acid and that for late-onset VAP piperacillin/
tazobactam. Combination therapy is not 
used. Antimicrobial therapy for patients 
with possible VAP was delayed until 
microbiology results were available. Patients 
with Acinetobacter isolates were not treated 
unless this was the sole pathogen in a case of 
possible VAP, when nebulised amikacin was 
the treatment of choice. Data were analysed 
according to the first episode of suspected 
VAP with the hypothesis that delays in 
initiating antimicrobials at this time would 
affect outcome.
Endpoints of the study were duration of 
mechanical ventilation, length of stay in the 
TICU and mortality rate. Categorical data 
were analysed using the χ2 or Fisher’s exact 
tests and continuous data using Student’s 
t-test. Differences in outcome between 
patients with possible and probable VAP 
were considered significant at p<0.05.
Results
A total of 288 patients were admitted to the 
TICU at IALCH during the study period, 
of whom 106 (36.8%) were suspected to 
be developing pneumonia. There were 84 
(79.2%) males and 22 (20.8%) females, 
with a median age of 29 years (interquartile 
range (IQR) 21 - 37) and a median injury 
severity score (ISS) of 31 (IQR 24 - 38). The 
mechanism of injury was predominantly 
blunt, with 77 (72.6%) having been injured in 
motor vehicle collisions, 17 (16.1%) having 
sustained non-vehicular blunt trauma, and 8 
(7.5%) having gunshot wounds, 3 (2.8%) stab 
wounds and 1 (0.9%) a snakebite. A total of 
247 positive cultures were obtained, of which 
168 (68.0%) were Gram-negative, 58 (23.4%) 
Gram-positive and 21(8.5%) fungal. Eleven 
Table 1. Distribution of early and late VAP, ISS, duration of mechanical ventilation, 
length of TICU stay and mortality in patients with possible and probable VAP
Possible VAP Probable VAP p-value
Early v. late VAP, n (%) 0.82
Early 22 (35.5) 12 (38.7)
Late 40 (64.5) 19 (61.3)
ISS, median (IQR) 34 (25 - 41) 34 (25 - 43) 0.79
Ventilation (days), median (IQR) 11 (8 - 16) 10 (8 - 15) 0.32
LOS (days), median (IQR) 16 (12 - 21) 13 (11 - 19) 0.45
Mortality, n (%) 8 (12.9) 5 (16.1) 0.75
LOS = length of stay.
Table 2. Distribution of the commonest Gram-negative pathogens between early and late VAP
Pathogen 
Early VAP
n (%)
Late VAP
n (%)
Gram-negative
 Acinetobacter baumannii (N=46) 8 (17.4) 38 (82.6)
Klebsiella pneumoniae (N=32) 5 (15.6) 27 (84.4)
 Haemophilus influenzae (N=25) 17 (68.0) 8 (32.0)
 Pseudomonas aeruginosa (N=17) 1 (5.9) 16 (94.1)
Proteus mirabilis (N=15) 1 (6.7) 14 (93.3)
Enterobacter spp. (N=10) 1 (10.0) 9 (90.0)
Escherichia coli (N=9) 3 (33.3) 6 (66.7)
Moraxella catarrhalis (N=8) 5 (62.5) 3 (37.5)
Gram-positive
Staphylococcus aureus (N=43) 17 (39.5) 26 (60.5)
 Streptococcus pneumoniae (N=9) 6 (66.7) 3 (33.3)
Other streptococci and enterococci (N=6) 3 (50.0) 3 (50.0)
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different species of Gram-negative and 7 of 
Gram-positive organisms were cultured. Of 
the 106 patients, 13 did not fulfil the criteria 
for VAP (in 8 VAP was suspected <48 hours 
after intubation and mechanical ventilation, 
in 3 respiratory flora were isolated after 
suspected aspiration, and in 2 Candida was 
the sole isolate). These were excluded from 
analysis, leaving a total of 93 patients. Of 
these 93, 57 (61.3%) had a single episode 
of suspected VAP, 22 (23.6%) two episodes 
and the remaining 14 (15.1%) three or more 
episodes, with a maximum of five in a 
patient ventilated for 72 days. Based on the 
first episode of VAP, 62 patients (66.7%) 
were diagnosed as having possible and 31 
(33.3%) probable VAP. The distribution and 
outcomes of possible and probable and early 
and late VAP are shown in Table 1.
The commonest Gram-positive and 
Gram-negative pathogens in early and late 
VAP are documented in Table 2, and their 
susceptibilities in Tables 3 and 4.
The most prevalent Gram-negative 
organ ism in early VAP was Haemophilus 
influenzae (38%). All isolates were suscep-
tible to amoxicillin/clavulanate. In addition 
to being the most common isolate in late 
VAP, A. baumannii was the most prevalent 
Gram-negative isolate overall and almost 
five times more common in late as opposed 
to early VAP. Forty-three (93.4%) of the 46 
isolates of A. baumannii were multidrug 
resistant, susceptible only to colistin (100%) 
and amikacin (96%). Of the 43 patients 
in whom multidrug-resistant (MDR) A. 
baumannii was cultured, 6 (14%) were 
offered therapy, 5 with nebulised amikacin 
and 1 with intravenous colistin. All but 
1 patient with MDR A. baumannii survived, 
the sole death occurring in a patient with 
overwhelming uncontrolled abdominal sep-
sis, retroperitoneal necrotising fasciitis and 
multiple organ failure.
Of the 32 K. pneumoniae isolates, 28 
(87.5%) were susceptible to amoxicillin/
clavu lanate, 3 (9.3%) were extended-
spectrum beta-lactamase (ESBL)-positive 
and susceptible to ciprofloxacin, and one 
was susceptible only to meropenem. There 
were 9 E. coli isolates, of which 2 were 
ESBL-positive and 7 were susceptible to 
amoxicillin/clavulanate. Of the 15 isolates 
of P. mirabilis, 4 (26.7%) were ESBL-
positive and 11 (73.3%) were susceptible to 
amoxicillin/clavulanate. There were no MDR 
P. aeruginosa isolates; all were susceptible to 
piperacillin/tazobactam, ciprofloxacin and 
meropenem. All 10 Enterobacter spp. were 
susceptible to ciprofloxacin and meropenem. 
Serratia spp., Aeromonas spp. and Citrobacter 
spp. were rare isolates.
Among the Gram-positive organisms 
there were 43 isolates of S. aureus, of which 
4 were vancomycin-sensitive methicillin-
resistant S. aureus (MRSA) and arose during 
episodes of late VAP. All 6 isolates of S. 
pneumoniae were susceptible to penicillin.
Thirty-one patients were treated empiri-
cally for probable VAP, prescriptions being 
correct in 28 cases (90.3%). Among the 3 
patients with incorrect prescriptions, ESBL 
K. pneumoniae resistant to amoxicillin/
clavu lanate was isolated in 1 patient with 
early VAP, and E. aerogenes resistant to 
piperacillin/tazobactam was cultured in 2 
patients with late VAP. In this group, 1 death 
occurred in an elderly man with severe 
traumatic brain injury and major blunt 
thoracic and abdominal trauma. Although 
inappropriate therapy may have contributed 
to his death, age and the extent of injury 
placed him in the probable non-survivor 
category. In the probable VAP cohort, no 
deaths were attributable to withdrawal of 
non-beneficial therapy due to futility.
Antimicrobials were commenced in 34 
(54.8%) of the 62 patients with possible 
VAP, and not prescribed in the remaining 
28 (45.2%). Of the latter, 24 recovered 
without antimicrobials and 4 died, no 
deaths being directly attributable to failure 
to treat nosocomial pneumonia. Death was 
due to withdrawal of non-beneficial therapy 
in 3 patients with severe traumatic brain 
injury and to retroperitoneal fasciitis in the 
remaining patient following the breakdown 
of a colonic anastomosis.
There was no significant difference in 
mortality between the 34 patients with 
possible VAP who were commenced on 
directed therapy and the 31 with probable 
Table 3. Antimicrobial susceptibility of the commonest Gram-negative pathogens
Gram-negative pathogens
Co-amox
 n (%)
Pip/taz
n (%)
Cipro
n (%)
Amik
n (%)
Merop
n (%)
Colistin
 n (%)
A. baumannii (N=46) 0 0 3 (6.5) 44 (95.7) 3 (6.5) 46 (100.0)
K. pneumoniae (N=32) 28 (87.5) 28 (87.5) 31 (96.9) 32 (100.0) 32 (100.0) 32 (100.0)
H. influenzae (N=25) 25 (100.0) 25 (100.0) 25 (100.0) Not drug of 
choice
Not drug of 
choice
Not drug of 
choice
P. aeruginosa (N=17) Not drug of 
choice
17 (100.0) 17 (100.0) 17 (100.0) 17 (100.0) 17 (100.0)
P. mirabilis (N=15) 11 (73.3) 11 (73.3) 15 (100.0) 15 (100.0) 15 (100.0) Intrinsic 
resistance
Enterobacter spp. (N=10) Not drug of 
choice
Not drug of 
choice
10 (100.0) Not drug of 
choice
10 (100.0) 10 (100.0)
E. coli (N=9) 7 (77.8) 7 (77.8) 9 (100.0) 9 (100.0) 9 (100.0) 9 (100.0)
M. catarrhalis (N=8) 8 (100.0) 8 (100.0) Not drug of 
choice
Not drug of 
choice
Not drug of 
choice
Not drug of 
choice
Co-amox = amoxicillin/clavulanate; Pip/taz = piperacillin/tazobactam; Cipro = ciprofloxacin; Amik = amikacin; Merop = meropenem.
Table 4. Antimicrobial susceptibility of the commonest Gram-positive pathogens
Gram-positive pathogens 
Penicillin
n (%)
Cloxacillin
n (%)
Vancomycin
n (%)
S. aureus (N=43) N/A 39 (90.7) 43 (100.0)
S. pneumoniae (N=6) 6 (100.0) Not drug of choice 6 (100.0)
RESEARCH
199       February 2016, Vol. 106, No. 2
VAP who were commenced on empirical antimicrobials (11.7% v. 
16.1%; p=0.79). Excluding the 4 deaths due to withdrawal of non-
beneficial therapy and uncontrolled abdominal sepsis, the overall 
mortality rate in patients with possible VAP, including those who 
were not offered antimicrobials, was 6.4% v. 16.1% in the probable 
group (p=0.29).
Discussion
Antimicrobials are an integral component of the management 
of sepsis,[5] and virtually all agree that the sooner appropriate 
antimicrobials are given, the better the outcome is. In addition to a 
delay in antimicrobial therapy, inappropriate prescriptions to which 
the pathogen is resistant are associated with decreased survival.[8] The 
recommendation is therefore to commence early broad-spectrum 
empirical therapy while awaiting microbiological confirmation, and 
then de-escalate as necessary.[9] Although minimising inappropriate 
prescriptions, this policy risks creating collateral damage and 
inducing bacterial resistance. Based on data showing that early 
appropriate administration of antimicrobials improves outcome 
in severe sepsis and septic shock, the same premise has been 
extrapolated to less-severe infections without proof of benefit. In 
patients with uncomplicated sepsis, the evidence for the timing 
of antimicrobial administration is contentious[10] and there are no 
studies substantiating the need for the same approach as is used in 
severe sepsis or septic shock. In fact, evidence to the contrary has 
been presented.[11] In the absence of haemodynamic instability or 
worsening organ function, there is no reported relationship between 
the timing of treatment and outcome. Moreover, the unwarranted 
use of broad-spectrum empirical antimicrobials in sepsis without 
organ dysfunction or hypotension may potentiate bacterial resistance 
without conferring benefit. Awaiting microbiological confirmation 
of the inciting pathogen and using directed therapy appears to be 
acceptable practice.
The pathogens isolated in our study were similar to those 
previously reported for VAP in the critically injured,[12] where 
Gram-negative organisms of the Enterobacteriaceae family 
predominated, especially in late VAP. Gram-positive species were 
less common, S. aureus being isolated most frequently. Among 
the pathogens we encountered few ESBL-producing organisms or 
MRSA, for which there are a number of explanations. Firstly, we 
have a strict infection control policy. Secondly, we have adopted 
a policy of antimicrobial stewardship and prescriptions based on 
microbiological surveillance. Thirdly, our patient population is 
young and antimicrobial naive; at the time of the first episode of 
VAP, only 40% had received prior antimicrobials.
Patients treated in the TICU are a unique population compared 
with those admitted to general medical and surgical intensive care 
units (ICUs). The TICU is exclusively for critically injured patients 
who require mechanical ventilation and are generally an otherwise 
well population free from chronic medical conditions and with no 
previous hospital visits or use of antimicrobials. Owing to ethical 
constraints regarding informed consent, and the knowledge that it 
does not impact on the immediate management or outcome of life-
threatening injuries,[13] routine HIV testing is not undertaken.[14]
Although the isolated flora may be similar in ICUs, reasons 
for bacterial resistance to antimicrobials vary, the commonest 
being previous antimicrobial exposure, the overuse of broad-
spectrum agents and selective pressure. Despite suggestions that 
the differentiation between early and late VAP is irrelevant and that 
all patients should be treated with broad-spectrum agents,[15] our 
data confirm that this distinction remains useful when deciding on 
empirical therapy. The vast majority of pathogens in early VAP in our 
patients were community-acquired flora susceptible to amoxicillin/
clavulanate, and indiscriminate use of broad-spectrum antimicrobials 
would encourage development of resistant strains.
MDR A. baumannii was the most common organism isolated in 
late VAP. Owing to its natural multidrug resistance and low virulence 
and pathogenicity, the unit policy is not to treat MDR Acinetobacter 
unless it is the sole pathogen in possible VAP that fails to improve. 
Of the 43 patients in whom MDR A. baumannii was cultured, only 
6 were offered therapy, mainly in the form of inhaled/nebulised 
amikacin. There was 1 fatality due to uncontrolled retroperitoneal 
fasciitis following a faecal leak. Based on these data, we suggest that 
treating all Acinetobacter isolates is unnecessary and will promote 
bacterial resistance.
The high incidence of possible pneumonia in our cohort reflects 
the difficulties in confirming the diagnosis of VAP. This is especially 
problematic in patients with blunt thoracic trauma and the systemic 
inflammatory response syndrome. Fever, progressive changes in 
chest auscultation and radiographs and a positive sputum culture 
are common before resolution of the underlying lung injury. That 
said, if there is diagnostic doubt and no immediate need for therapy, 
our results confirm that in patients with possible VAP, awaiting 
definitive microbiologal results before commencing antimicrobials 
does not compromise outcome. Furthermore, due to an improvement 
in clinical signs in almost 50% of patients with possible VAP, 
antimicrobials were not prescribed. However, this policy may only 
be implemented in association with an effective microbiology service 
employing urgent Gram staining and rapid susceptibility testing. 
In addition, although the incidence of VAP is reported to be 
significantly higher in the critically injured, the outcome is better 
than for non-trauma patients.[16] The most likely explanation is 
that young, previously healthy males comprise the vast majority of 
the trauma population, whereas non-trauma patients are an older 
population, often with comorbidities. In that light, our findings may 
not be universally applicable to all critically ill populations.
A number of myths concerning antimicrobials perpetuate the 
prescription of broad-spectrum drugs. It is a misconception that 
sicker patients require what are erroneously termed ‘stronger 
antibiotics’. Firstly, regardless of the severity of the underlying disease, 
the susceptibility of pathogens remains identical for that pathology. 
For example, the organisms involved in appendicitis are the same 
whether the disease is localised or causing generalised peritonitis, 
and as such there is no need initially to use a broader-spectrum agent. 
The same premise holds true for early VAP, where H. influenzae is 
almost universally susceptible to amoxicillin/clavulanate. Secondly, 
with the exception of bacteriostatic v. bactericidal antibiotics, there is 
no such entity as a stronger antibiotic, only antibiotics with a broader 
spectrum of action. To minimise the development of antimicrobial 
resistance, the principle should be to use a drug with the narrowest 
spectrum against the most likely pathogens. This requires a working 
knowledge of local flora and of their antibiotic sensitivities, achieved 
through bacteriological surveillance. Thirdly, there is no proof that 
empirical combination therapy has any advantage over monotherapy 
if an appropriate single antimicrobial is selected.[17] The only patients 
in whom combination therapy appears to be beneficial are those 
in septic shock.[9] In the presence of effective microbiological 
surveillance, it is possible to achieve adequate empirical antimicrobial 
therapy over 90% of the time with the initial empirical choice of a 
single agent.[18] The TICU at IALCH subscribes to stewardship and 
employs an empirical antimicrobial policy based on surveillance. 
Lastly, there is a mistaken belief that newer drugs are superior to 
their elderly counterparts. This is untrue – the drug of choice for a 
penicillin-sensitive organism is penicillin.
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Combating the problem of drug resistance requires a ‘multipronged’ 
approach. In addition to antibiotic stewardship and surveillance, 
early convincing diagnosis of infection would greatly improve use of 
antibiotics and in turn address the problem of antibiotic resistance. 
Conventional microbiological culture, performed by most laboratories 
worldwide, requires several days for isolation, identification and 
antimicrobial susceptibility testing of the pathogen. As a result 
there is a delay in the identification of resistant bacteria, which 
results in the inappropriate use of antimicrobials. Rapid diagnostic 
methods must therefore have the capability of influencing early 
antibiotic decision-making to allow for more appropriate treatment 
of antibiotic-resistant bacterial infection, as well as minimisation of 
unnecessary use of broad-spectrum agents.[19] May et al.[20] described 
a novel strategy for the rapid diagnosis of VAP, using exhaled breath 
condensate fluid obtained from heat-moisture exchangers to provide 
a substrate for testing with the polymerase chain reaction to identify 
bacterial DNA. The advantage of molecular diagnostic platforms 
lies in the ability to diagnose pathogens and their accompanying 
resistance genes rapidly. The challenge to ICU clinicians is how to 
use antimicrobials most effectively to maximise patient benefits while 
minimising the emergence of resistance. In this, the use of rapid 
diagnostics may hold the key.[19]
Despite numerous warnings in the medical literature about the 
threat of bacterial resistance, indiscriminate antimicrobial prescribing 
continues unabated, with as many as 64% of prescriptions being 
deemed either unnecessary or an inappropriate choice.[21] Our data 
confirm that delaying antimicrobial prescriptions in situations of 
doubtful sepsis, or omitting therapy altogether, does not adversely 
affect outcome. The real possibility of a post-antibiotic era in the 
21st century has been highlighted by the World Health Organization 
(WHO) report on antimicrobial resistance,[22] and concern has now 
reached political level[23,24] with proposals to provide incentives 
to the pharmaceutical industry to develop new antimicrobials. 
This approach is short sighted and ineffective for a number of 
reasons. History will undoubtedly repeat itself: the development 
of each new antimicrobial has been followed by resistance, the 
normal evolutionary process of mutation and natural selection 
conferring a survival benefit. In the modern pharmaceutical market, 
antimicrobials are not a cost-effective investment for research and 
development and, ironically, pressure from the pharmaceutical 
industry to use their broad-spectrum products has contributed to the 
current situation. The most logical and practical short- and long-term 
solutions to preserve what drugs we currently possess are education, 
bacteriological surveillance and antimicrobial stewardship.[18] 
Antimicrobial stewardship is of paramount importance, especially in 
areas with frequent antimicrobial use. Pivotal to success are interested 
clinicians and microbiologists, knowledge of local resistance patterns, 
and an antimicrobial policy that optimises the choice, dose and 
duration of therapy.[18] The particular patient population, local 
epidemiology, and prior antimicrobial exposure in each specific ICU 
need to be considered when considering empirical antimicrobial 
therapy.
The WHO has warned that bacterial resistance has become a 
global health emergency, and in the not-too-distant future there is 
the very real possibility that previously treatable common infections 
and minor injuries may become fatal. Unless urgent action is taken, a 
bacterial apocalyptic fantasy may become reality.[22] 
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